Published in Nature Medicine, this study found a 73% lower risk of suicidal ideation in patients with obesity or diabetes treated with semaglutide compared to those treated with other diabetes or obesity medications
Accurate guidance makes planning easier
D., Aryandono, T., Lazuardi, L
In addition, a combination regimen of PARPi and copanlisib (a PI3K inhibitor) was tested in phase I/II trials (NCT03586661 and NCT05295589) in patients with BRCA-mutated, resistant ovarian cancer
The proposed mechanisms range from well-validated (FDA-approved GLP-1 agonists for weight loss) to highly speculative (epitalon, thymosin alpha-1, MOTS-c) with limited or no human clinical validation
How long does semaglutide-related diarrhea typically last